8:00 am Morning Registration & Networking Coffee

8:50 am Chair’s Opening Remarks

From AI & Predictive Tools to Proteome-Wide Screens: Exploring Screening Approaches for Effective Binder Discovery

9:00 am Leveraging AI & Cryo-EM for Discovery of Molecular Glues


  • Harnessing revolutionary new tools in artificial intelligence and atomic resolution cryo-electron microscopy (cryo-EM) to discover novel druggable protein interfaces
  • Showcasing how our platform enables us to design and discover potent interfacial glues and allosteric inhibitors that influence protein-protein interactions
  • Presenting on our rapid processes for hit discovery and hit-to-lead optimization result in accelerated paths to development candidates for unmet patient needs

9:30 am Conducting Proteome-Scale Induced Proximity Screens to Discover Novel Hits

  • Mikko Taipale Assistant Professor - Molecular Genetics & Research Chair - Functional Proteomics & Proteostasis, University of Toronto


  • Understanding how proteome-scale induced proximity screens can reveal novel effectors of central biochemical processes
  • Utilizing unbiased screening to facilitate discovery of unexpected effectors
  • Exploring the potential for drug discovery using the aforementioned techniques

10:00 am Utilizing DEL as a Primary Discovery Engine for Induced Proximity Approaches


  • Designing a DEL collection that addresses both traditional and challenging target space
  • Presenting DEL affinity screening of targets and ligases for bifunctional degrader discovery
  • Showcasing a DEL to degrader case study

10:30 am Morning Break & Speed Networking


Our structured networking is the ideal opportunity to get face-to-face time with many of the brightest minds working in the field & introduce yourself to the attendees that you would like to have more in-depth conversations with. Benchmark against industry leaders & establish meaningful business relationships to pursue for the rest of the conference & beyond

11:30 am Simulating the Conformational Basis of Induced Proximity to Predict Event-driven Pharmacology for Enhanced Drug Discovery

  • Bryce Allen Co Founder & Chief Executive Officer, Differentiated Therapeutics Inc.


  • Learning structure-based representations from molecular dynamics simulations to predict and assess induced proximity mechanisms
  • Evaluating lysine proximity to E2 ligase to inform degrader design and prioritization for synthesis
  • Application of our Auto/dx platform to quantitatively predict and improve degradation profiles by integrating live-cell kinetic data

Improving Heterobifunctional Design & Testing To Increase Efficacy

12:00 pm Reimagining Druggability Using Chemoproteomic Platforms


  • Understanding the rational discovery and design of molecular glues
  • Developing novel induced proximity based therapeutic modalities
  • Learning about DUBTACs for targeted protein stabilization

12:30 pm Expanding the Toolbox to Enable New Induced Proximity Mechanisms for TPD


  • Importance of cellular kinetics for understanding event-driven pharmacology
  • Hijacking luminescent reporter tags for inducible degradation of a target
  • General lysosomal recruitment strategies coupled with detection methods for membrane protein TPD

1:00 pm Networking Lunch

2:00 pm Linking Structure to Function for Heterobifunctionals: Structural Considerations that Affect Function

  • Arvin Dar Professor, Icahn School of Medicine at Mount Sinai


  • Utilizing steric considerations to promote the interaction between protein of interest and effector machinery
  • Using linker size and chemistry to positively affect heterobifunctional design and function
  • How to optimize heterobifunctional structure for increased membrane solubility and oral drug availability

2:30 pm PANEL DISCUSSION: Rational Design versus “Serendipity”: Deciding When to Solve the Mechanism of Action

  • Dan Nomura Professor, University of California
  • Arvin Dar Professor, Icahn School of Medicine at Mount Sinai
  • Bryce Allen Co Founder & Chief Executive Officer, Differentiated Therapeutics Inc.
  • Alex Gaither Vice President and Head of Oncology, USA Site Head, Exscientia


  • Navigating the latest advancements in the quest for rational design of heterobifunctional molecules and its advantages
  • Should we focus on optimizing phenotypic screening approaches for discovering and testing novel molecules
  • Comparing the two approaches and evaluating their pros & cons

3:15 pm Poster Session & Networking

3:45 pm Accurately Measuring Ternary Complexes to Better Elucidate Mechanisms of Action


  • Examining common approaches to understanding protein-protein interactions through ternary complex measurement
  • Understanding the challenges with elucidating ternary complexes
  • Advancing predictive technology to visualise ternary complexes

4:15 pm Targeting Oncogenic RAS(ON) by Engaging Cyclophilin A & Inducing Inhibitory Tri-Complexes

  • Kyle Seamon Senior Scientist II, Revolution Medicines Inc.


  • Design of natural product-inspired molecules that induce a tri-complex between Cyclophilin A and the active state of RAS
  • Tri-complex inhibitors of RAS(ON) are potent, orally bioavailable, and active in vivo in preclinical models of RAS-driven cancers
  • Formation of tri-complex enables novel bRo5 functionality, including covalent targeting of mutations beyond KRASG12C

Inducing Proximity to Drive Immune Interfaces on the Cell Surface to Alter Disease Relevant Biology

4:45 pm Proximity-based Discovery & Manipulation of Cell Surface Proteins to Influence Disease-Relevant Pathways


  • Examining post-translational modifications and steric proximity paradigms to influence disease-relevant biology
  • Using induced proximity tools to characterize immune synapses between cells
  • Manipulating cell surface protein proximity to alter signal transduction
  • Establishing bispecific screening paradigms to identify productive protein pairings

5:15 pm Using Modified Cytokines to Target Immune Receptors for Selective Response Towards Cancer

  • Nikolai Kley Founder & Chief Executive Officer, Orionis Biosciences LLC


  • Designing modified cytokines that have low affinity/activity towards their natural receptors
  • How to use induced proximity to restore/drive interactions between the modified cytokine and its natural receptor(s)
  • Optimizing selectivity/pharmacology of the modified cytokine by focusing on localizing activity to clinically relevant targets for alleviating disease

5:45 pm Chair’s Closing Remarks & End of Day One